Cargando...
PARK2 loss promotes cancer progression via redox-mediated inactivation of PTEN
Cancer and Parkinson disease (PD) derive from distinct alterations in cellular processes, yet there are pathogenic mutations that are unequivocally linked to both diseases. Here we expand on our recent findings that loss of parkin RBR E3 ubiquitin protein ligase (PRKN, best known as PARK2)—which is...
Gardado en:
| Publicado en: | Mol Cell Oncol |
|---|---|
| Main Authors: | , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado: |
Taylor & Francis
2017
|
| Assuntos: | |
| Acceso en liña: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5706935/ https://ncbi.nlm.nih.gov/pubmed/29209642 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/23723556.2017.1329692 |
| Tags: |
Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!
|